Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BCMA-targeting therapy

- PMLiVE

Sandoz completes acquisition of GSK’s cephalosporin business

The acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network

dengue fever mosquito

WHO has recommended GSK’s malaria vaccine for children

This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children

- PMLiVE

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

- PMLiVE

GSK/Merck KGgA cancer drug fails in third trial

Fusion protein, bintrafusp alfa – the centrepiece of the 2019 GSK/Merck partnership – has failed to meet its latest trial endpoint and the trial is to be discontinued

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

- PMLiVE

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

New results follow success of BMS’ Breyanzi in the same patient population and setting

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

Kite partners with Shoreline Biosciences to develop allogeneic cell therapies

The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront payment

Bristol Myers Squibb logo

BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links